Dr Vasilios Karavasilis, Consultant Medical Oncologist
Dr Vasilios Karavasilis
Consultant Medical Oncologist
Dr Vasilios Karavasilis
Consultant Medical Oncologist
Dr Vasilios Karavasilis
Consultant Medical Oncologist
Areas of expertise
- Chemotherapy
- Sarcoma
- Soft tissue sarcomas
- Skin cancer
- Cancer prevention and screening
About Dr Vasilios Karavasilis
GMC number: 6106585
Year qualified: 1997
Place of primary qualification: University of Ioannina
Dr Karavasilis is a distinguished member of the sarcoma team at University College London Hospitals (UCLH). He specialises in the systemic treatment of adult patients with various types of sarcomas, including bone sarcomas and gastrointestinal stromal tumours (GISTs). In addition to his role at UCLH, Dr Karavasilis serves as an Assistant Professor of Oncology at Aristotle University of Thessaloniki, Greece, where he previously held the position of Director of Medical Oncology.
With over 15 years of experience in clinical trials, Dr Karavasilis has a profound interest in clinical and translational research in sarcomas. His research primarily focuses on discovering novel agents for the treatment of these cancers. His dedication to advancing medical knowledge and improving patient outcomes is evident in his extensive work in this field.
Dr Karavasilis is highly skilled in administering chemotherapy and has a comprehensive understanding of sarcomas, including soft tissue sarcomas. His expertise and commitment to patient care make him a valuable asset to both UCLH and the broader medical community.
Dr Karavasilis joined UCLH bringing with him a wealth of knowledge and experience. His contributions to oncology and his ongoing research efforts continue to make a significant impact on the treatment of sarcomas.
Professional memberships
Articles by Dr Vasilios Karavasilis
Assessing the clinical value of micrornas in formalin-fixed paraffin-embedded liposarcoma tissues: overexpressed mir-155 is an indicator of poor prognosis
Prognostic evaluation of epidermal growth factor receptor (egfr) genotype and phenotype parameters in triple-negative breast cancers